Want to see ATHE full AI Analyst Report?
ATHE Stock Chart & Stats
$4.54
$0.13(2.75%)
At close: 4:00 PM EDT
$4.54
$0.13(2.75%)
Day’s Range― - ―
52-Week Range$2.66 - $5.89
Previous Close$4.56
Volume3.89K
Average Volume (3M)13.05K
Market Cap
$84.04M
Enterprise Value$78.21M
Total Cash (Recent Filing)$49.15M
Total Debt (Recent Filing)$98.35K
Price to Earnings (P/E)―
Beta1.25
Next Earnings
Mar 04, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.96
Shares Outstanding18,194,204
10 Day Avg. Volume16,981
30 Day Avg. Volume13,055
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.56
Price to Sales (P/S)12.18
P/FCF Ratio-5.79
Enterprise Value/Market Cap0.93
Enterprise Value/Revenue20.40
Enterprise Value/Gross Profit21.07
Enterprise Value/Ebitda-3.94
Forecast
1Y Price Target
$12.50Price Target Upside175.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.35
Revenue Forecast (FY)$2.50M
Bulls Say, Bears Say
Bulls Say
FDA-confirmed Registrational PathwayOfficial FDA End-of-Phase-2 alignment that supports a single pivotal Phase 3 plus confirmatory evidence materially de-risks ATH434’s development. This regulatory clarity reduces design uncertainty, shortens time-to-readout planning, and strengthens the path toward an efficient NDA submission.
Validated MRI Biomarker (QSM)A validated, disease-specific imaging biomarker improves diagnostic precision and objective endpoint measurement. QSM's validation supports trial enrichment, reduces measurement noise, and enhances the credibility of efficacy signals—structurally improving trial design and regulatory confidence.
High Gross Margins And Revenue GrowthSustained gross margins above 90% and recent 46% revenue growth indicate a scalable revenue mix and efficient cost structure at the gross level. Over 2–6 months, these fundamentals imply that incremental revenue can disproportionately improve operating leverage as development programs mature or commercial opportunities arise.
Bears Say
Negative Operating And Free Cash FlowsConsistent negative operating and free cash flows create a structural funding gap as the company advances to a pivotal Phase 3. This increases dependency on external financing, risks program delays if capital is constrained, and can force dilution or reprioritization of R&D spend over the medium term.
Persistent Unprofitability And Negative ROENegative ROE and historical net/EBIT losses indicate the company has yet to convert scientific progress into shareholder returns. Structurally, continued unprofitability limits reinvestment capacity, raises long-term shareholder return risk, and increases pressure to achieve successful Phase 3 results to justify future capitalization.
Reliance On Capital Markets And Potential DilutionActive use of shelf registration statements and filings to broaden quotation access signals structural dependence on equity markets to fund operations. For a clinical-stage biotech advancing an expensive Phase 3, this reliance increases dilution risk and creates ongoing financing overhang over the coming months.
Alterity Therapeutics News
ATHE FAQ
What was Alterity Therapeutics Ltd’s price range in the past 12 months?
Alterity Therapeutics Ltd lowest stock price was $2.66 and its highest was $5.89 in the past 12 months.
What is Alterity Therapeutics Ltd’s market cap?
Alterity Therapeutics Ltd’s market cap is $84.04M.
When is Alterity Therapeutics Ltd’s upcoming earnings report date?
Alterity Therapeutics Ltd’s upcoming earnings report date is Mar 04, 2027 which is in 200 days.
How were Alterity Therapeutics Ltd’s earnings last quarter?
Alterity Therapeutics Ltd released its earnings results on Feb 25, 2026. The company reported -$0.415 earnings per share for the quarter, missing the consensus estimate of -$0.25 by -$0.165.
Is Alterity Therapeutics Ltd overvalued?
According to Wall Street analysts Alterity Therapeutics Ltd’s price is currently Undervalued.
Does Alterity Therapeutics Ltd pay dividends?
Alterity Therapeutics Ltd does not currently pay dividends.
What is Alterity Therapeutics Ltd’s EPS estimate?
Alterity Therapeutics Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Alterity Therapeutics Ltd have?
Alterity Therapeutics Ltd has 18,194,204 shares outstanding.
What happened to Alterity Therapeutics Ltd’s price movement after its last earnings report?
Alterity Therapeutics Ltd reported an EPS of -$0.415 in its last earnings report, missing expectations of -$0.25. Following the earnings report the stock price went up 2.945%.
Which hedge fund is a major shareholder of Alterity Therapeutics Ltd?
Currently, no hedge funds are holding shares in ATHE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alterity Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.50 (175.33% Upside)
$12.50 (175.33% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
43.18%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
481.25%
Trailing 12-Months
Company Description
Alterity Therapeutics Ltd
Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent experimental therapy, ATH434, has completed Phase I clinical trials targeting Parkinson's disease. The company is also advancing PBT2, a compound that has successfully undergone Phase IIa clinical testing for Alzheimer's disease. Established in 1997, the entity was formerly known as Prana Biotechnology Limited before rebranding to Alterity Therapeutics Limited in April 2019, and its main operations are based in Melbourne, Australia.
ATHE Stock 12 Month Forecast
Average Price Target
$12.50
▲(175.33% Upside)
Technical Analysis
Ownership Overview
―
Insiders
<0.01% Mutual Funds
0.34% Other Institutional Investors
99.65% Public Companies and
Individual Investors